Conversely, BRAF and TP53 mutations were associated with worse OS, as has been demonstrated in other historic cohorts of metastatic CRC [23,[27], [28], [29]], PIK3CA gain-of-function and PTEN loss-of-function tumor mutations were associated with improved outcomes, suggesting potential targeted therapy options for CRCs that develop peritoneal dissemination. The gene discussed is TP53; the disease is neoplasm.